DRW Securities’s Monte Rosa Therapeutics GLUE Stock Holding History

DRW Securities’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,296	Closed	-$235K	–	1159
2026 Q1	$235K	Buy	+14,296	New	+$273K	﹤0.01%	1022

Other funds holding GLUE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DRW Securities's GLUE Position: Q2 2026 in Review

DRW Securities sold out of Monte Rosa Therapeutics (GLUE) in Q2 2026, closing a stake of 14,296 shares — an estimated $235K sold.

DRW Securities first reported a position in GLUE in Q1 2026 and held it in 1 quarter. The position peaked at $235K in Q1 2026. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

DRW Securities reported no remaining Monte Rosa Therapeutics position as of Q2 2026 after selling out during the quarter.
DRW Securities sold 14,296 Monte Rosa Therapeutics shares in Q2 2026, an estimated $235K.
DRW Securities first reported a position in Monte Rosa Therapeutics in Q1 2026 and held it in 1 quarter.
DRW Securities's Monte Rosa Therapeutics position peaked at $235K in Q1 2026.
192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.